NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

On Tuesday, that startup— NewLimit —raised a $130 million Series B round led by venture capital giant Kleiner Perkins with ...

NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many ...

NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.

NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has raised a $130 million Series B led by Kleiner Perkins. New investors ...

On Tuesday, that startup—NewLimit—raised a $130 million Series B round led by venture capital giant Kleiner Perkins with contributions from new and existing investors including Khosla Ventures ...